Table 5.
Patient characteristics and pMMA and uMMA values of a subset of individuals from the MARLINA trial. Median and IQR of pMMA and uMMA at V3 and V7 group by treatment group and MMA levels.
| MMA levels | Group | n | Median V3 | IQR V3 | Median V7 | IQR V7 |
|---|---|---|---|---|---|---|
|
pMMA nmol/L | ||||||
| High | Placebo | 68 | 300 | 116 | 330 | 126 |
| High | Linagliptin 5 mg | 71 | 302 | 155 | 347 | 128 |
| Mid | Placebo | 80 | 138 | 82.5 | 169 | 98.7 |
| Mid | Linagliptin 5 mg | 80 | 133 | 123 | 134 | 96.5 |
|
uMMA µmol/mmol Creatinine | ||||||
| High | Placebo | 32 | 4.150 | 6.780 | 3.730 | 3.830 |
| High | Linagliptin 5 mg | 23 | 3.850 | 2.760 | 4.870 | 3.540 |
| Mid | Placebo | 77 | 1.140 | 0.972 | 1.200 | 1.530 |
| Mid | Linagliptin 5 mg | 86 | 0.968 | 0.857 | 0.978 | 0.666 |
| Low | Placebo | 16 | 0.324 | 0.198 | 0.287 | 0.131 |
| Low | Linagliptin 5 mg | 11 | 0.292 | 0.0998 | 0.235 | 0.167 |
IQR interquartile range; pMMA plasma methylmalonic acid; uMMA urine methylmalonic acid; V3 baseline; V7 end of study.